Basiliximab

A chimeric murine-human monoclonal antibody that functions as an INTERLEUKIN 2 RECEPTOR antagonist by binding to the alpha chain (CD25 ANTIGEN) of the interleukin-2 receptor on the surface of activated T-LYMPHOCYTES. It is used in the prevention of acute graft rejection episodes in patients undergoing renal transplantation.

Also Known As:

Networked: 297 relevant articles (26 outcomes, 33 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Huang, Xiao-Jun: 4 articles (01/2022 - 01/2020)
2.	Wang, Yu: 4 articles (01/2022 - 01/2020)
3.	Liu, Jing: 4 articles (04/2012 - 11/2003)
4.	Xue, Mei: 4 articles (04/2012 - 11/2003)
5.	Huang, He: 3 articles (01/2022 - 01/2017)
6.	Mo, Xiao-Dong: 3 articles (01/2022 - 01/2020)
7.	Xu, Lan-Ping: 3 articles (01/2022 - 01/2020)
8.	Zhang, Xiao-Hui: 3 articles (01/2022 - 01/2020)
9.	Brennan, Daniel C: 3 articles (01/2021 - 11/2006)
10.	Wang, Heng-Xiang: 3 articles (04/2012 - 11/2003)

Related Diseases

1.	Infections 02/14/2022 - "⑥Univariate and multivariate analyses showed that late aGVHD (OR=3.121, 95%CI 1.770-5.503, P<0.001) , Minnesota score high-risk group before medication (OR=3.591, 95%CI 1.931-6.679, P<0.001) , active infection before medication (OR=1.881, 95%CI 1.029-3.438, P=0.040) , and impairment of important organ function caused by non-GVHD (OR=3.100, 95%CI 1.570-6.121, P=0.001) were independent risk factors affecting the efficacy of basiliximab. " 01/01/2022 - "Machine learning was used to develop a protocol that maximized the efficacy of basiliximab while maintaining acceptable levels of infection risk. " 02/01/2002 - "The efficacy of basiliximab was assessed by conventional parameters, and tolerability was assessed by the incidence of adverse events, infections, and laboratory test result abnormalities. " 11/01/2023 - "We compared the outcomes of infection and biopsy-proven acute rejection (BPAR) according to the type of induction agent (basiliximab and r-ATG [4.5 mg/kg]). " 01/01/2023 - "Multivariate analysis showed that induction with ATG was associated with a lower risk of rejection at 1 year (OR, .31; 95% CI, .09-.94; p = .039) with no impact on the incidences of CMV infection (HR, 2.06; 95% CI, .54-7.89; p = .292), CAV (HR, .30; 95% CI, .04-2.58; p = .275), and mortality (HR, .39; 95% CI, .09-1.82; p = .233) compared to basiliximab induction. "
2.	Graft vs Host Disease (Graft-Versus-Host Disease) 01/01/2020 - "Basiliximab may also be used for prophylaxis and treatment of graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT); however, the PK of basiliximab in this setting are not known. " 07/01/2015 - "Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis." 08/01/2003 - "Treatment of graft-versus-host disease after liver transplantation with basiliximab followed by bowel resection." 07/01/2015 - "Haploidentical HSCT using basiliximab for graft-versus-host disease (GVHD) prophylaxis in 10 patients with leukemia was retrospectively compared to ATG for GVHD prophylaxis in 24 patients. " 02/14/2022 - "[Efficacy of basiliximab in the treatment of 87 cases of steroid-refractory or steroid-dependent acute graft-versus-host disease]."
3.	Ulcerative Colitis 07/01/2003 - "Basiliximab appears to be effective at inducing remission in steroid-resistant ulcerative colitis. " 07/01/2003 - "Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis." 05/15/2006 - "Taken in combination with previously reported data, basiliximab shows particular promise in moderate steroid-resistant ulcerative colitis." 07/01/2003 - "Ten patients with steroid-resistant ulcerative colitis received a single bolus of 40 mg of intravenous basiliximab plus steroid treatment in an open-label, uncontrolled, 24-week study. " 08/01/2012 - "We investigated the efficacy and safety of basiliximab as a corticosteroid-sensitizing agent in patients with corticosteroid-refractory ulcerative colitis (UC). "
4.	Diabetes Mellitus 09/15/2000 - "Basiliximab is associated with a significant reduction in acute rejection and an excellent safety profile in renal transplant recipients with and without diabetes mellitus. " 04/01/2017 - "Basiliximab may be effective in reducing de novo diabetes mellitus. " 09/15/2000 - "Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. " 10/01/1999 - "Basiliximab was studied in renal allograft recipients and subgroups of recipients of living-related and cadaveric transplants, and in patients with diabetes mellitus. " 04/01/2017 - "Basiliximab significantly decreased the incidence of de novo diabetes mellitus after liver transplantation (RR=0.56; 95% CI: 0.34-0.91; P=0.02). "
5.	Delayed Graft Function 03/01/2010 - "We sought to evaluate the efficacy of renal transplant induction protocols using Basiliximab based on the rates of acute rejection episodes (ARE) and delayed graft function (DGF) of infectious complications in the first 6 months posttransplant, as well as patient and graft survivals. " 03/01/2007 - "In conclusion, this study confirmed the beneficial effects of addition of basiliximab to the immunosuppressive schema of patients with delayed graft function." 03/01/2007 - "The aim of this study was to evaluate the use of basiliximab in first renal transplant recipients with delayed graft function, defined by the need for dialysis in the first week posttransplantation. " 05/01/2006 - "This randomized, open-label study compared the efficacy, tolerability, and costs of low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart) versus standard-dose RATG (2 mg/kg per d) in 33 consecutive high-risk renal transplant recipients (living-related transplant recipients, sensitized patients or patients who received another transplant, and patients with delayed graft function) over 6 mo of follow-up. " 01/01/2022 - "In the basiliximab group, the duration of dialysis ≥ 3 years (p = 0.0191), cold ischaemia time ≥ 1,020 minutes or expected delayed graft function (p < 0.0001) are independent risk factors for graft loss (p = 0.0097). "

Related Drugs and Biologics

1.	Steroids
2.	Monoclonal Antibodies
3.	Immunosuppressive Agents (Immunosuppressants)
4.	Cyclosporine (Ciclosporin)
5.	Mycophenolic Acid (Cellcept)
6.	Adrenal Cortex Hormones (Corticosteroids)
7.	thymoglobulin
8.	Tacrolimus (Prograf)
9.	Creatinine
10.	Antiviral Agents (Antivirals)

Related Therapies and Procedures

1.	Therapeutics
2.	Kidney Transplantation
3.	Liver Transplantation
4.	Hematopoietic Stem Cell Transplantation
5.	Bone Marrow Transplantation (Transplantation, Bone Marrow)